Emapalumab, also known as emapalumab-tykv , represents a novel clinical agent uniquely targeting free interleukin-6 complex alpha (sIL-6Rα). The exceptional action involves targeted interaction to sIL-6Rα, successfully blocking its ability to engage with membrane-bound IL-6R and subsequently acti
```text
A Deep Dive into the The SGN-70 Drug This SGN-70 antibody represents a novel approach in the field of oncology, specifically targeting the CD22 antigen expressed on various leukemias and lymphomas. Developed by the researchers, it functions as an cell-mediate